Mylan executives said Friday that Perrigo Co.’s strategy of remaining a standalone company won’t work, and that the Irish over-the-counter drug specialist should drop its opposition to merging with Mylan.

“Their strategy is flawed and simply will not produce sustainable growth over the longer term,” executive chairman Robert J. Coury said during a conference call discussing Mylan’s third quarter results.

He said Perrigo’s contention that Mylan’s offer is bad for Perrigo’s shareholders “is simply preposterous and disingenuous.”

Mr. Coury, CEO Heather Bresch and president Rajiv Malik were so thorough in marching analysts through projections of why Perrigo’s prospects as an independent company are limited that one analyst commented it sounded like Mylan was telling investors to short Perrigo’s stock. Shorting is a strategy used by investors who think a company’s stock is poised to fall.

Advertise with us

Mr. Coury replied that Mylan has acquired many businesses that it did not like as standalone ventures, but that realized greater potential once they were joined with Mylan. “I think that Perrigo is going to be no different,” he said.

Perrigo took issue with Mr. Coury’s comment on the call that criticism of Mylan’s corporate governance practices is a “red herring.” Some analysts have contended Mylan’s shares trade at a discounted price because of its governance practices, an assessment Perrigo echoed in a statement issued Friday.

“Mylan has shown through its own governance choices ... why there is a governance discount applied to its shares,” the statement said.

After Perrigo’s board rejected Mylan’s takeover bid earlier this year, Mylan, which reincorporated in the Netherlands but maintains its operational headquarters in Cecil, took its proposal directly to Perrigo shareholders in September.

Mylan is offering to acquire each of their shares for $75 in cash and 2.3 Mylan shares. The tender offer is slated to expire Nov. 13, but could be extended.

Advertise with us

In an Oct. 25 letter to Perrigo chairman and CEO Joseph Papa, Mr. Coury offered to meet to discuss how to get the most out of the merger and how the combined company would be governed. On the call Friday, Mr. Coury said he was willing to put Perrigo representatives on the board of the combined company.

Mylan’s third quarter earnings topped analyst estimates, but revenue fell short of expectations.

The drug maker said third quarter net income dropped 14 percent to $428.6 million, or 83 cents per share. Revenue jumped 29 percent to $2.7 billion.

Mylan said excluding special items, adjusted earnings rose 23 percent to $1.43 per share. Analysts had forecast adjusted earnings of $1.38 per share and revenue of $2.8 billion.

Mylan shares closed Friday at $44.09, off $1.69. They are down 22 percent this year.

Len Boselovic: lboselovic@post-gazette.com or 412-263-1941.